Belite Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	6.82	6.82	3.95	2.38	2.06
Research & Development	24.84	24.84	8.87	7.42	3.69
Operating Expenses	31.67	31.67	12.82	9.8	5.74
Operating Income	-31.67	-31.67	-12.82	-9.8	-5.74
Interest Expense / Income	0.03	0.03	0.02	0	0.02
Other Expense / Income	-0.07	-0.07	-0.19	-0.13	-0.01
Pretax Income	-31.62	-31.62	-12.65	-9.67	-5.75
Income Tax	0.01	0.01	0	0	0
Net Income	-31.63	-31.63	-12.65	-9.67	-5.75
Shares Outstanding (Basic)	27	27	20	10	9
Shares Outstanding (Diluted)	27	27	20	10	9
Shares Change	33.12%	33.12%	108.74%	8.87%	-
EPS (Basic)	-1.19	-1.19	-0.63	-1.01	-0.65
EPS (Diluted)	-1.19	-1.19	-0.63	-1.01	-0.65
Free Cash Flow	-29.9	-29.9	-11.85	-7.53	-4.46
Free Cash Flow Per Share	-1.12	-1.12	-0.59	-0.79	-0.51
EBITDA	-31.2	-31.2	-12.43	-9.64	-5.71
Depreciation & Amortization	0.4	0.4	0.2	0.03	0.02
EBIT	-31.6	-31.6	-12.63	-9.67	-5.73

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).